COMP <GO>
SABS vs EIKN // EV/EBITDA & P/E VALUATION
SAB Biotherapeutics Inc. (NASDAQ) VS. Eikon Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SABS 2
— EIKN 0
■ METRIC PARITY
LAST: $3.23 (+0.94%) • MKT CAP: $293.9M
valuation
—
LAST: $5.35 (-3.43%) • MKT CAP: $289.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SABS VS. EIKN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SABS | EIKN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.40% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.55% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.07 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.2 | 28.2 | +31.97 | SABS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $293.9M | $289.8M | $4.1M | SABS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SABS REV | EIKN REV | SABS GROSS % | EIKN GROSS % | SABS FCF | EIKN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$45.7M | — |
| FY 2024 | $1.3M | — | — | — | -$34.6M | — |
| FY 2023 | $2.2M | — | — | — | -$25.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SABS // BETA —
EIKN // BETA —